EMPagliflozin After Aortic Valve Replacement

Summary

The study is a randomized, placebo-controlled, and double-blinded trial in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR). After AVR, patients will be randomized 1:1 to empagliflozin (SGLT2i) or placebo to investigate whether empagliflozin is superior to placebo in reducing left ventricular mass and improve symptoms to 6 months.

Timeline

Start

2024-02-14

Primary completion

2026-05-08

Completion

2026-05-18

Publications

• Sorensen LM, Reinert MS, Raja AA, de Backer O, Bieliauskas G, Schou M, Jensen J, Moller ELR, Linde JJ, Kofoed KF, Kuhl JT, Procida K, Petersen JK, Havers-Borgersen E, Kober L, Fosbol E. Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial. Am Heart J. 2026 Jul;297:107432. doi: 10.1016/j.ahj.2026.107432. Epub 2026 Mar 27.

Drugs

Indications